Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 3, Pages 289
Publisher
MDPI AG
Online
2021-03-13
DOI
10.3390/biomedicines9030289
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study
- (2021) Francesco Plotti et al. Biomedicines
- β1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters
- (2020) Fabian Baltes et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model
- (2020) Enes Taylan et al. GYNECOLOGIC ONCOLOGY
- Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer
- (2020) Anqi Wu et al. Frontiers in Genetics
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Immunotherapy in Ovarian Cancer
- (2019) Weimin Wang et al. Surgical Oncology Clinics of North America
- Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
- (2019) Alday-Parejo et al. Cancers
- Immunotherapy in Ovarian Cancer: Are We There Yet?
- (2019) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
- (2019) Deborah K. Armstrong et al. Journal of the National Comprehensive Cancer Network
- Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment
- (2019) Brown et al. Cancers
- Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer
- (2019) Katharina Dötzer et al. Cancers
- Reversing microtubule‐directed chemotherapeutic drug resistance by co‐delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer
- (2019) Weihong Zheng et al. CELL BIOLOGY INTERNATIONAL
- Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer
- (2019) Adam J. Camblin et al. Scientific Reports
- Productive Cross-Talk with the Microenvironment: A Critical Step in Ovarian Cancer Metastasis
- (2019) Aziz et al. Cancers
- The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells
- (2019) Kathleen Wantoch von Rekowski et al. Biomolecules
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis
- (2018) Quanwu Sun et al. OncoTargets and Therapy
- Role of tumor microenvironment in ovarian cancer pathobiology
- (2018) Alia Ghoneum et al. Oncotarget
- The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
- (2017) Jun Li et al. Oncotarget
- Integrins as Therapeutic Targets: Successes and Cancers
- (2017) Sabine Raab-Westphal et al. Cancers
- Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review
- (2017) et al. Cancers
- 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease
- (2016) M. K. Wilson et al. ANNALS OF ONCOLOGY
- A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
- (2016) B. Milojkovic Kerklaan et al. INVESTIGATIONAL NEW DRUGS
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Alpha2beta1 integrin in cancer development and chemoresistance
- (2015) Dalila Naci et al. SEMINARS IN CANCER BIOLOGY
- Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin
- (2014) Jennifer M. Scalici et al. GYNECOLOGIC ONCOLOGY
- Comparative Meta-analysis of Prognostic Gene Signatures for Late-Stage Ovarian Cancer
- (2014) Levi Waldron et al. JNCI-Journal of the National Cancer Institute
- Prognostic Significance of α5β1-integrin Expression in Cervical Cancer
- (2013) Hua-Yi Wang et al. Asian Pacific Journal of Cancer Prevention
- Increased expression of α5β1-integrin is a prognostic marker for patients with gastric cancer
- (2013) J. Ren et al. Clinical & Translational Oncology
- Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
- (2013) Weiva Sieh et al. LANCET ONCOLOGY
- Cadherin-17 interacts with α2β1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis
- (2013) R A Bartolomé et al. ONCOGENE
- Integrins and metastasis
- (2013) Kirat Kumar Ganguly et al. Cell Adhesion & Migration
- Integrin Targeted Therapeutics
- (2012) Melissa Millard et al. Theranostics
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Phase I Study of E7820, an Oral Inhibitor of Integrin -2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
- (2011) M. Mita et al. CLINICAL CANCER RESEARCH
- Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis
- (2011) J V Burnier et al. ONCOGENE
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
- (2009) Andreas du Bois et al. CANCER
- Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via 5-Integrin, which Is a Therapeutic Target
- (2008) K. Sawada et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started